Clinical trials injecting the virus into patients to treat cancer are underway
In May 2022, a clinical trial to
Imugene and City of Hope Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
https://www.cityofhope.org/city-hope-and-imugene-announce-first-patient-dosed-phase-1-trial-test-cancer-killing-oncolytic
First Patient Injected With Experimental Cancer-Killing Virus in New Clinical Trial
https://www.sciencealert.com/first-patient-injected-with-experimental-cancer-killing-virus-in-new-clinical-trial
The drug candidate CF33-hNIS (Vaxinia) , developed by the City of Hope and licensed to Imugene, is a type of oncolytic virus that has been genetically modified to selectively kill cancer cells. CF33-hNIS is based on the poxvirus and self-replicates in infected cancer cells, causing the cells to rupture and release viral particles that act as antigens . The virus particles stimulate the immune system to selectively attack nearby cancer cells.
The research team has already conducted animal experiments on CF33-hNIS and has shown that CF33-hNIS shrinks tumors such as colon cancer, lung cancer, breast cancer, ovarian cancer, and pancreatic cancer. 'Our previous study was that oncolytic viruses stimulate the immune system to respond to and kill cancer,' said Dr. Daneng Li, Principal Investigator of Medical Oncology and Therapeutics at the City of Hope. In addition, it has been demonstrated to stimulate the immune system to be more responsive to other immunotherapies, including immune checkpoint inhibitors . '
The City of Hope and Imugene, which had been approved to begin Phase I clinical trials of CF33-hNIS in March 2022, announced on May 17 that they had 'administered CF33-hNIS to the first patient.' .. In Phase I clinical trials, low-dose experimental treatment will be given first to confirm the safety of CF33-hNIS and the tolerability of side effects.
A total of 100 subjects in Phase I clinical trials are planned, all of whom are adults with metastatic or advanced solid tumors and must have received at least two standard treatments in the past. It has become. Subjects enrolled in the study will receive low doses of CF33-hNIS by direct or intravenous injection into the tumor and will record data such as the frequency and severity of adverse effects.
If CF33-hNIS is considered to be safe and tolerable in early experimental results, its interaction with pembrolizumab , which is used in existing cancer immunotherapy, will also be investigated. Secondary indicators such as how small the tumor was due to CF33-hNIS will be analyzed at a later date, but clinical trials are expected to take two years, and detailed results will be available in a little more time. It is believed that it will take.
If the treatment with CF33-hNIS is officially approved by the US Food and Drug Administration (FDA), it will be approved as a treatment for malignant melanoma that has progressed to stage 4 'talimogene laherparepvec (T-). This is the second cancer treatment method using a virus, following the one using a virus called 'VEC)'.
Government approval for the first time to use a virus to destroy cancer cells-GIGAZINE
by Miles Smith
Related Posts:
in Science, Posted by log1h_ik